Jessica Steen, OD, FAAO

At the Envision Summit 2025 in San Juan, Puerto Rico, Jessica Steen, OD, FAAO talked with glaucoma surgeons on the importance of comanaging patients throughout their lifetime.

A newer class of topical glaucoma therapy, Rho kinase inhibitors, works to lower intraocular pressure in patients with glaucoma via a novel mechanism. In this podcast, Mitch Ibach, OD, FAAO, of Vance Thompson Vision in Sioux Falls, SD, and Jessica Steen, OD, FAAO, of the Nova Southeastern University College of Optometry in Fort Lauderdale, FL, will discuss the mechanism of action of these agents, along with data supporting their use within the broader range of topical glaucoma therapies.

EnVision Summit optometry faculty Sherrol Reynolds, OD, FAAO; Katie Rachon, OD, FAAO, Dipl ABO; Ashley Wallace-Tucker, OD, FAAO, FSLS, Dipl ABO; Jessica Steen, OD, FAAO, Dipl ABO; and Cecelia Koetting, OD, FAAO, Dipl ABO; express excitement for the upcoming conference and why optometrists should attend.

Jessica Steen, OD, FAAO, Dipl-ABO, discussed ophthalmic considerations for patients undergoing treatment with antibody drug conjugates for gynecologic cancers at this year's conference.

Optometrists are often the first to notice ocular adverse effects from systemic medication. When should optometrists reach out to prescribing doctors?

Evaluating images for quality, artifacts, and segmentation errors.

Novel drops for a variety of indications are under investigation.

Jessica Steen, OD, FAAO, gave an ophthalmic therapeutic update during the 2022 American Academy of Optometry Meeting.

Jessica Steen, OD, FAAO, shares what she wishes she knew before entering the field.

Jessica Steen, OD, FAAO, shares highlights from her VEW 2022 presentation, "Ophthalmic therapeutics update."

Jessica Steen, OD, FAAO, shares key takeaways from her AOA 2022 presentation, "Problem Solving in Glaucoma Management."

Jessica Steen, OD, FAAO, shares why she views the development of OCT-angiography as her personal favorite technological advancement in eyecare.

FDA review pathway looks to balance innovation with data review

Use of intravitreal biologics, steroids, and improvements to vitreoretinal surgical techniques have improved the prognosis of vitreoretinal conditions. Ocular hypertension, which may lead to secondary open-angle glaucoma, is a common complication both short- and long-term following intravitreal injection of anti-VEGF or steroid agent and PPV—especially when silicone oil is used as a tamponade agent. Understanding these potential risks is key to early detection, diagnosis, and management following vitreoretinal procedures.